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ovarian cancer cell lines derived 
from non-serous carcinomas 
migrate and invade more 
aggressively than those derived 
from high-grade serous carcinomas
Amelia Hallas-potts, John C. Dawson & C. simon Herrington  
the term ovarian cancer describes a heterogeneous group of tumours that grow in the ovary but are 
not necessarily of ovarian origin. Recent genomic analysis has shown that many of the most commonly 
used ovarian cancer cell lines have been mischaracterised, leading to erroneous conclusions and a gap 
in the translation of laboratory research into novel treatments for patients. Here, we use 10 epithelial 
ovarian cancer cell lines to investigate 2D migration, cell cycle parameters and 3D invasion behaviour 
into different substrates and find significant differences between the behaviours of cell lines from 
different origins. Cell lines derived from non-serous carcinomas migrated more quickly and were more 
likely to invade into Matrigel and collagen I substrates than cell lines derived from high-grade serous 
carcinomas. However not all cell lines derived from non-serous carcinomas exhibited similar invasive 
behaviour. These findings may reflect differences in the behaviour of the primary tumour types from 
which the cell lines were derived, given that high-grade serous carcinomas typically expand and spread 
over peritoneal surfaces. these results provide the basis of an in vitro model for identifying differences 
between ovarian cancer tumour types.
Ovarian cancer is the most lethal gynaecological disease in women and, in 2018, there will be approximately 
300,000 new diagnoses of ovarian cancer worldwide1. Despite the improvement in prognosis for most solid 
tumours, epithelial ovarian cancer prognosis remains relatively unchanged2, with only one major new treatment 
introduced in the last 30 years3. The term ovarian cancer describes several histotypes which show distinct cellular 
origin, molecular aberrations and disease progression in patients4; however, this heterogeneity is not reflected in 
the treatments currently available. Furthermore, the term ovarian cancer may be misleading as many ovarian can-
cers arise from non-ovarian tissue. The single consolidating feature of ovarian cancers is the localised dissemina-
tion of tumour cells to the ovary and pelvic organs2. Ovarian cancer is difficult to identify clinically since patients 
often present with non-specific symptoms such as bloating and fatigue5. Indeed, 80% of women are diagnosed at 
an advanced stage where 5-year survival is only 5% compared to 92% if the cancer is detected early5. For women 
diagnosed at a late stage, the treatment options remain limited and, even if the cancer is detected early, the chance 
of relapse is 70% within 18 months5.
Epithelial ovarian cancer accounts for 90% of all ovarian cancer diagnoses6; it encompasses all cancers that 
arise from epithelium and involve the ovary7. The most common histological types are high-grade serous, 
low-grade serous, endometrioid, clear cell and mucinous carcinomas. High-grade serous ovarian carcinomas 
(HGS) commonly arise in the epithelium of the fallopian tube fimbria and subsequently present as apparently 
ovarian tumours after implantation in the ovary (Fig. 1)7. These tumours present at an advanced stage, are fast 
growing and spread throughout the peritoneal cavity8. Endometrioid and clear cell carcinomas are non-serous 
tumours (NS) and have strong links to endometriosis, a disease that affects 10% of the female population9. 
Ovarian endometriosis is thought to arise from retrograde menstruation and results in endometrial tissue 
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growing outside the uterine body, most commonly on the ovaries (Fig. 1)7. NS tumours generally present at 
an early stage where they have not spread beyond the ovary but have formed a large tumour mass. Non-serous 
tumours have been shown to be mutationally distinct from serous ovarian tumours10 but the differences in inva-
sive behaviour of these tumours are poorly described.
In 2013 Domcke et al.11 found that many of the most commonly used ovarian cancer cell lines do not genet-
ically resemble the tumour types they have been used to investigate. This was confirmed on a different but over-
lapping panel of cell lines in 2014 by Beaufort et al.12. These findings highlight a new challenge for ovarian cancer 
research as many previous findings are now misleading and researchers must re-evaluate their choice of cell lines. 
Therefore our study focuses on distinguishing the behaviour of ovarian cancer cell lines from different origins to 
determine whether cell lines with the same genomic characterisation show similar behaviours. We use two panels 
of five cell lines characterised by Domcke et al.11 and Beaufort et al.12; one panel represents high-grade serous car-
cinoma and the other non-serous carcinoma (endometrioid and clear cell). We show clear behavioural differences 
between high-grade serous and non-serous ovarian cancer cell lines and propose the use of these cell lines as an 
in vitro model to investigate distinct ovarian cancer tumour types.
Results
Criteria for the cell line panel. The panel of cell lines was categorised based on the genomic profiles out-
lined by Domcke et al.11 and Beaufort et al.12. On this basis, OVCAR3, COV318, PE01, PE04 and FUOV1 were 
considered high -grade serous (HGS) and A2780, OVCAR8, OAW42, SKOV3 and TOV21G non-serous (NS). 
The keratinocyte-derived HACAT cell line was included as a non-ovarian control.
Ns cell lines migrate faster than HGs cell lines. 2D migration behaviour was assessed by relative 
wound density using the IncuCyte ZOOM® wound healing assay (Fig. 2).
Statistical analysis at 30 hours showed that the relative wound density of NS cells was significantly higher than 
HGS cells (Fig. 2A, Mann-Whitney U test p < 0.001), highlighting that NS cell lines migrate faster than HGS 
to close the wound. Statistically, the HGS and NS panels of cell lines show distinct migration behaviour when 
considered as groups. However, analysis of the behaviour of individual cell lines shows variability between lines 
(Fig. 2B). In particular, COV318 and A2780 cells show different migration behaviour from the other cells in the 
HGS and NS panels respectively. COV318 migrates faster than the other HGS cell lines, behaving more similarly 
to NS cells; whereas A2780 migrates slower than the other NS cell lines, behaving more similarly to the HGS 
panel. This is evident for wound density at all time points over the 60 hours (Fig. 2C).
Two-way repeated measures ANOVA was used to further investigate differences between cell line behaviour 
over time, identifying statistically significant differences between the cell lines (Fig. 2C, p < 0.001). Comparison 
of the behaviour of each cell line at each time point using Tukey’s multiple comparisons showed that HACAT, 
SKOV3, OAW42 and OVCAR3 behave significantly differently from each other and all other cell lines at >75% of 
time points. However, the other cell lines divided into two groups, A and B (Fig. 2C). Group A is composed of the 
cell lines OVCAR8, TOV21G and COV318, which show no significant difference in behaviour from each other 
at >75% of time points. Group B is composed of the cell lines A2780, PEO1, PEO4 and FUOV1 which show no 
significant difference in behaviour from each other at all time points. Estimation of cell line doubling times by 
cell counting showed no systematic relationship between doubling time and migration behaviour: A2780 14 hr, 
HACAT 15 hr, TOV21G 18 hr, OAW42 25 hr, SKOV3 36 hr, OVCAR3 47 hr, OVCAR8 54 hr, PEO1 82 hr, PEO4 
94 hr, COV318 75 hr, FUOV1 98 hr and see Fig. 2.
Figure 1. Anatomy of the female reproductive system and cancer biology of the ovary. The inset depicts models 
of high-grade serous (HGS, blue) and non-serous (NS, yellow) ovarian cancer pathogenesis. Most HGS ovarian 
carcinomas arise in the fallopian tube fimbria and implant on the ovary whereas most NS ovarian carcinomas 
arise from ovarian endometriosis which is thought to occur from retrograde menstruation. Dashed lines depict 
processes (retrograde menstruation or implantation of HGS cells), solid lines depict the progression of disease 
(ovarian endometriosis to NS carcinoma).
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Fewer HGS than NS cell lines are in G0/G1 phase of the cell cycle. Flow cytometry was used to 
determine the cell cycle behaviour of the panels of cell lines at 80% confluence. The percentages of cells in G0/G1, S 
and G2/M phase were quantified. Significant differences were found between HGS and NS cell lines at each phase 
of the cell cycle, with significantly fewer HGS cells in G0/G1 phase compared to NS cells (G1/G0: t-test: p = 0.001 
Fig. 3A). Conversely, significantly more of the HGS cell population was in S and G2/M phases compared to NS 
cell lines (S: Mann-Whitney U test p = 0.033. G2/M: t-test: p = 0.008, Fig. 3A). Notably, however, although HGS 
cell line cell cycle behaviour is significantly different from NS cell lines overall, there is overlap between the cell 
line groups (Fig. 3B,C).
NS cell lines are more likely to invade than HGS cell lines. The inverted transwell invasion assay was 
used to determine the invasive potential of HGS and NS cell lines into Matrigel. As described previously13 cells 
that invade above 45 µm into the matrigel were considered invasive; cells below 45 µM are not considered invasive 
as it is likely they have only migrated across the transwell membrane. By these criteria, only 3 of the 11 cell lines 
investigated showed evidence of invasion, all of them NS cell lines (Fig. 4). TOV21G and SKOV3 were the most 
Figure 2. Wound healing behaviour. (A). Relative wound density at 30 hr for high-grade serous (HGS) 
cell lines compared to non-serous (NS) cell lines (median ± IQR). HGS median = 14.36 ± 19.03, NS 
median = 61.38 ± 34.9 Mann-Whitney U test, p < 0.001, U = 1795. (B). Relative wound density at 30 hr for 
each cell line (median ± IQR). (C). Relative wound density over 60 hours (mean ± SEM). Two-way repeated 
measures ANOVA identifies two populations of cell lines (p < 0.001). Group A cell lines (COV318, TOV21G, 
OVCAR8) show no significant difference between relative wound density at >75% of time points (p < 0.005). 
Group B cell lines (A2780, PEO1, PEO4, FUOV1) show no significant difference between relative wound 
density at all time points (p < 0.005). (HGS: blue, NS: yellow, Control: grey). Experiments were carried out in 
triplicate on 3 separate occasions for each cell line. ***p < 0.001.
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Figure 3. Characterisation of cell cycle behaviour. (A). The percentage of cells at each phase of the cell 
cycle for non-serous (NS) compared to high-grade serous (HGS) cell lines (median ± IQR). G0/G1: HGS 
median = 65.5 ± 17.6; NS median = 82.8 ± 17.2 Independent samples t-test, equal variance p = 0.001, t = −3.70, 
df = 28. S: HGS median = 18.5 ± 7.4; NS median = 12.2 ± 18.4. Mann Whitney U test, p = 0.033, U = 61.5 G2/M: 
HGS median = 14.7 ± 7; NS median = 9.4 ± 7.3. Independent samples t-test, equal variance p = 0.008, t = 2.879, 
df = 28. (B). The percentage of cells at each phase of the cell cycle for HGS cell lines (mean ± SEM). C. The 
percentage of cells at each phase of the cell cycle for NS cell lines (mean ± SEM). Experiments were carried out 
in triplicate on 3 separate occasions for each line.
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invasive cell lines; OVCAR8 showed only a very small amount of invasion; no other cell line invaded above 45 µm 
in any experiment.
Invasive behaviour of ovarian cancer cell lines differs in collagen matrix compared to Matrigel. 
This experiment was carried out on the 2 most invasive cell lines (TOV21G and SKOV3), the 2 least migratory 
cell lines (FUOV1 and PEO1) and the 2 cell lines that behaved differently from the other cell lines in the HGS and 
NS groups in the migration assay (A2780 and COV318). In the collagen invasion assay, only 2 cell lines invaded 
into the collagen matrix, both NS cell lines (TOV21G and A2780). None of the HGS cell lines proliferated on top 
of or invaded into the collagen matrix (Fig. 5). SKOV3 showed prominent invasive behaviour in Matrigel but the 
cells did not attach or invade into the collagen matrix. This finding supports previous research which showed that 
SKOV3 does not attach or invade into collagen14 or form intraperitoneal tumours15.
The collagen invasion assay is more qualitatively informative than the Matrigel invasion assay as it is possible 
to visualise the morphology of the invading cells by taking a cross-section of the collagen matrix. TOV21G cells 
formed a thin layer of cells on top of the collagen, degraded the collagen or proliferated in a cavity and invaded 
as single cells with mesenchymal morphology. The single cells invaded outwards from the proliferative cell layer. 
This spindle-like morphology is characteristic of sarcomatous tumour cell invasion16,17 commonly associated 
with epithelial-mesenchymal transition (EMT)18. A2780 cells formed a thick proliferative cell layer on top of 
the collagen and invaded in small clumps of cells. This cluster invasion phenotype is characteristic of epithelial 
tumour cells16.
Discussion
Previous studies investigating ovarian cancer cell line behaviour commonly use cell lines such as OVCAR3 and 
SKOV3 and focus on investigating how genetic manipulation or drug treatments can increase or decrease invasive 
and migratory behaviour. However, to our knowledge the endogenous behaviour of these cell lines stratified by 
histotype has not been carried out previously. We show that high-grade serous carcinoma-derived (HGS) cell 
lines behave differently from cell lines derived from non-serous carcinomas (NS) in four different behavioural 
assays. Our findings highlight the need for careful cell line selection in order that the data derived from these cell 
lines can be interpreted appropriately.
In general, the NS cell lines migrated more rapidly than HGS cell lines, which seems counter-intuitive as HGS 
tumours are typically more clinically aggressive, spread throughout the peritoneum and have a worse patient 
prognosis compared to NS tumours. Moreover, NS ovarian tumours commonly present at an early stage before 
metastasis has occurred. However, establishing cell lines from primary tumours in vitro is very difficult and many 
Figure 4. Invasion into Matrigel. (A). Representative z-step confocal microscopy images taken at 15 µm 
intervals through the Matrigel for each cell line. Cells were stained with SYTO™9 green fluorescent nucleic 
acid stain. (B). Larger representative images from A showing TOV21G, SKOV3 and OVCAR8 invasion over 
45 µM. (C). Invasion above 45 µm for each cell line (median ± IQR), normalised to the most invasive cell line. 
Experiments were carried out on 3 separate occasions for each cell line; 4 images were captured per repeat per 
cell line.
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of the genetic mutations required to immortalise cell lines are found only in late-stage tumours, consistent with 
the observation that most cell lines have the potential to grow as metastases19. In keeping with this argument, 
TOV21G was derived from stage 3 clear cell carcinoma20; and SKOV3 and OAW42 were both derived from 
ascitic fluid (from post-chemotherapy patients)21,22, which is associated with higher stage disease. Given that NS 
tumours are normally diagnosed and treated prior to metastasis, the behaviour differences of these cell lines can-
not therefore be used to replicate and understand the behaviour of primary NS tumours; however, they are useful 
for understanding the rare but more aggressive advanced stage NS disease.
It is important to highlight that although the HGS and NS cell lines showed different migration behaviour 
when analysed as distinct groups, the behaviours of individual cell lines did not segregate as clearly. A2780 is an 
NS cell line but behaved similarly to PEO1, PEO4 and FUOV1 which are HGS cell lines. Similarly, COV318 is 
classified genomically as a HGS cell line but behaves similarly to TOV21G and OVCAR8 which are NS cell lines. 
These findings highlight that, although these cell lines can be divided into different categories by their mutation 
profiles, their behaviours in vitro do not necessarily segregate the same way. Most importantly the cell lines do not 
all behave as expected based on their putative identity.
The link between cancer cell invasion and cell cycle arrest in G0/G1 is well documented23,24. Once a cell enters 
S phase it is committed to DNA replication, which is a very energy intensive process, making it unlikely that 
these cells can be involved in other cellular processes, such as invasion. The cell cycle findings provide evidence 
that the migration behaviour differences are not a result of proliferation. Furthermore, we found no systematic 
relationship between doubling time, estimated by cell count, and migration behaviour for the cell lines used in 
this study. For example, A2780, HACAT and TOV21G cells all had similar doubling times (14 hr, 15 hr and 18 hr 
respectively) but their migration behaviour was markedly different; A2780 migrated much more slowly than 
TOV21G and HACAT, failing to close the wound area after 60 hr. In contrast HACAT cells migrated quickly, clos-
ing the wound area in 33 hr but TOV21G cells took 60 hr despite a similar proliferation rate. These results are also 
in keeping with data derived from live imaging of invasion showing that cells in G1/G0 are more likely to invade 
and, if the same invasive cells cycle into S phase, they cease invasion until the cell cycle is complete24.
Similarly to migration, the finding that HGS cell lines are not invasive may seem unexpected. However, HGS 
tumours do not have to physically invade through tissue to seed metastatic tumours throughout the peritoneal 
cavity8. Even very large tumours only invade the superficial layers of the bowel and omentum and not the deeper 
layers8. It is rare to find HGS metastases to the bone or brain, which are common with other epithelial tumours 
such as breast and colon cancers which undergo several stages of intra-/extravasation before they seed metastases 
in other organs8. The behaviour of the NS cell lines is similarly counter-intuitive given that the disease is primarily 
non-metastatic. However, TOV21G was derived from the tumour of a patient diagnosed with stage 3 clear cell 
carcinoma20 and, anecdotally, patients with advanced stage NS tumours have a poor prognosis, similar to or even 
worse than those with HGS tumours, in keeping with the hypothesis that the behaviour of TOV21G replicates the 
rare advanced stage of the disease. Information on the origins of SKOV3 and OVCAR8 is limited21,25 but SKOV3 
Figure 5. Organotypic invasion assay. Representative images of haematoxylin and eosin (H&E) stained 
sections showing cell lines cultured on top of collagen/fibroblast matrices at day 10 of the organotypic invasion 
assay. Images captured using Hamamatsu Nanozoomer XR at 40X objective magnification. (A). High-grade 
serous (HGS) cell lines COV318, FUOV1 and PEO1. (B). Non-serous (NS) cell lines TOV21G, A2780 and 
SKOV3. TOV21G invaded to a maximum depth of 250 µm. A2780 invaded to a maximum depth of 150 µm. 
(C). Collagen/fibroblast matrix with no cell lines cultured on top. Experiments were carried out on 3 separate 
occasions for each cell line.
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was derived from ascitic fluid rather than primary tumour21,26,27. Given that the formation of ascites is associated 
with advanced disease the invasive behaviour exhibited by SKOV3 also represents the behaviour of advanced 
stage disease28. HGS cells are characterised by a TP53 mutation but OVCAR8, which is categorised as non-serous 
and behaves similarly to other NS cell lines, also has a TP53 mutation (in addition to other mutations typically 
associated with non-serous tumours). It is therefore unlikely that, in these cell lines, the differences in the migra-
tion and invasion behaviours of HGS compared to NS cells are driven by TP53 mutation as previously suggested 
by Ahn et al.29. Indeed, the most motile cell lines (including OVCAR8) have mutations in signalling pathways 
such as MAPK, PI3K and WNT11, which generally lead to overactivity in those pathways, and could explain the 
NS phenotype we observe. HGS cell lines characterised by only a TP53 mutation would not have this phenotype 
and would be susceptible to genomic instability. In parallel, clinical evidence supports the idea that HGS tumour 
cells do not have to migrate quickly to seed metastasis as the disease develops undetected over several years.
The differences in invasive behaviour between HGS and NS cell lines used in this study are supported by in 
vivo tumourigenicity experiments. Hernandez et al.30 compared the ability of a different but overlapping panel 
of ovarian cancer cell lines to form tumours in nude mice over 6 weeks. They found that OVCAR8, SKOV3 and 
A2780 had high tumourigenicity when injected intraperitoneally, whereas OVCAR3, PEO1 and PEO4 had low 
tumourigenicity. Although the cell lines were not stratified by histotype in the in vivo study, the tumourigenic cell 
lines OVCAR8, SKOV3 and A2780 are derived from NS tumours and the non-tumourigenic cell lines OVCAR3, 
PEO1 and PEO4 are derived from HGS tumours.
Replicating the tumour microenvironment in vitro is challenging. The transwell invasion assay uses Matrigel, 
an extract of Engelbreth-Holm-Swarm (EHS) tumour which contains basement membrane components. Matrigel 
is commonly used in invasion assays but its suitability as an in vitro basement membrane substitute has been 
challenged14,31. Furthermore, the epithelial ovarian cancer microenvironment is composed of various different 
proteins and cell types. Collagen I is the most abundant structural protein within the ovarian extracellular matrix 
(ECM)32; therefore we used the collagen/fibroblast organotypic invasion assay to determine whether ovarian 
cancer cell lines behave differently when they encounter an ECM component more replicative of the in vivo 
environment.
The heterogeneity of the NS cell lines compared to the HGS cell lines may in part be explained by the fact that 
the NS category encompasses cell lines which were derived from clear cell and endometrioid carcinomas20,21,33–35. 
However, this heterogeneity cannot be explained by differences in tumour origin or molecular profile as both 
are associated with endometriosis and they have a similar genomic landscape. The differences in behaviours of 
NS cell lines in Matrigel and collagen highlights the importance of the substrate and may be related to the ECM 
context that the original cell line was derived from. Although the details in the original paper are sparse, A2780 
was derived from untreated primary tumour material34. TOV21G was also derived from tumour material whereas 
SKOV3 was derived from ascites20,21. It is therefore interesting that TOV21G invades aggressively into both 
Matrigel and collagen, whereas SKOV3 shows invasion into Matrigel but not collagen; conversely A2780 invades 
aggressively into collagen but not Matrigel. Moreover, all the HGS cell lines apart from FUOV1 are derived from 
ascites35–39. Thus, overall, 2 of the 3 cell lines derived from primary tumours (TOV21G and A2780) attached and 
invaded into collagen but none of the cell lines derived from ascites exhibited this behaviour. This suggests that 
cell lines derived from the primary tumour have the ability to attach and invade into collagen whereas cell lines 
derived from ascites may not. This is consistent with the fact that tumour cells floating in ascitic fluid are able to 
survive and grow in suspension, without attachment to, or invasion into, a solid matrix.
Cell lines are vital as a first step to understanding molecular and behavioural changes that result in tumour 
development and progression. However, the current approach of using cell lines to investigate ovarian cancer, 
without stratifying by histotypes, is hindering the advancement of the field. Our data provide evidence that ovar-
ian cancer cell line behaviour correlates to some extent with tumour histotype and hence origin. However, the 
variability between cell lines indicates that behavioural characterisation should be taken into account, in addition 
to tumour histotype, origin and molecular profile, when interpreting the results of in vitro experiments using 
these cell lines.
Taken together these findings provide a basis for the selection of relevant ovarian cancer cell lines to investi-
gate the differences between HGS and NS tumours in vitro. Representative in vitro models will help overcome the 
current gap in the translation of laboratory research to novel therapies for ovarian cancer patients. Future research 
should focus on using appropriately selected cell lines for the development of in vitro models to understand the 
molecular and behavioural differences between ovarian tumour types.
Materials and Methods
All reagents were purchased from Thermo Fisher Scientific (Renfrew, UK) unless otherwise stated.
Cell culture. Human epithelial ovarian adenocarcinoma cell line SKOV3 was acquired from ATCC. Human 
epithelial ovarian adenocarcinoma cell lines NIH: OVCAR-3 (OVCAR3), OVCAR8, PEO1, PEO4, COV318 and 
FUOV1 were kindly supplied by David Melton from the University of Edinburgh. Human epithelial ovarian ade-
nocarcinoma cell lines A2780, TOV21G and OAW42 were kindly supplied by Charlie Gourley from the University 
of Edinburgh. Human keratinocyte cell line HACAT was kindly supplied by Lana Woolford from the University 
of Edinburgh. All cell lines were authenticated using STR profiling (Public Health England). Red fluorescent pro-
tein telomerase reverse transcriptase (TERT) immortalised fibroblasts (RTIF) generated from skin punch biopsies 
were a kind gift of Andrew Campbell (Beatson Institute, Glasgow). All cell lines were maintained in a humidified 
incubator at 37 °C with 5% CO2. OVCAR3, SKOV3, OVCAR8, PEO1, PEO4, COV318, FUOV1, A2780, TOV21G 
and OAW42 were cultured in RPMI Medium 1640 (1 × ) supplemented with 10% fetal calf serum (FCS), 1X 
non-essential amino acids (Sigma Aldrich, Irvine, UK), 100 µL/mL (v/v) penicillin-streptomycin, 1 mM sodium 
pyruvate (Sigma Aldrich) and 1 µL/mL bovine insulin (Sigma Aldrich). All ovarian cancer cell lines were cultured 
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in the same medium to control for biases due to varied levels of growth factors or different serum levels, in 
keeping with the approach of Beaufort et al.12. All of the lines had been acclimatised to this medium for at least 3 
months prior to experimentation. HACAT was cultured in DMEM (1×) + GlutaMAX supplemented with 10% 
FCS, 100 µL/mL (v/v) penicillin-streptomycin. Fibroblasts were cultured in DMEM (1×) +GlutaMAX supple-
mented with 10% FCS. Cell lines were routinely tested for mycoplasma contamination and all cell experiments 
were carried out in sterile conditions. Cell lines were passaged using 0.05% trypsin-EDTA (1×). All experiments 
were carried out with cell lines no more than 10 passages apart to ensure biological repeats and limit the muta-
tional effect of passaging. Cell lines were not synchronised prior to experimentation.
Wound healing assay. For each cell line, 100 µL of a 5 × 106 cells/mL cell suspension (5 × 105 cells) were 
seeded into every well of an ImageLock™ 96 well plate (Essen Bioscience, Hertfordshire, UK). The plate was then 
incubated at 37 °C, 5% CO2 for 4 hours (hr). After the incubation period, the 96 well WoundMaker™ (Essen 
Bioscience) was used to simultaneously create wounds in all wells. The plate was then washed twice with culture 
media (100 µL per well; media specific to cell line used) to remove any cell debris. 100 µL of normal cell culture 
media was then added to each well and the plate was placed inside the IncuCyte ZOOM® incubator system (Essen 
Bioscience). Plates were imaged every 3 hr for 60 hr. The percentage area covered by cells inside the wound area 
relative to the percentage area covered by cells outside of the wound area (relative wound density) at every time 
point was analysed. 3 technical repeats were carried out for each cell line and this procedure was repeated 3 times 
to ensure 3 biological repeats.
Flow cytometry. For each cell line, 5 × 105 cells were transferred to a fluorescence-activated cell sorting 
(FACS) tube and the content centrifuged for 5 minutes (min) at 400xg. To fix the cells, the supernatant was dis-
carded and the pellet resuspended in 300 μL PBS supplemented with 50% FCS. 900 μL of ice-cold 70% ethanol was 
then slowly added whilst gently tube vortexing. The samples were stored at 4 °C. On the day of analysis, 3 mL PBS 
was added to the samples and the content centrifuged for 5 min at 400xg. The supernatant was discarded and the 
pellet re-suspended in 300 μL PBS supplemented with 0.1 μL/mL DAPI, 0.1% Triton x100. The samples were then 
stored for 1 hr in the dark and analysed using flow cytometry (BD LSRFortessa X-20). This procedure was carried 
out with 3 biological repeats per cell line.
Inverted invasion assay. This method is a modified version of Hennigan et al.40. Matrigel (Corning, New 
York, USA) was diluted in a 1:1 ratio with 1% serum culture media. Then 100 μL of the dilute Matrigel was added 
into the centre of each Transwell (Corning) and the plate was incubated for approximately 1 hr at 37 °C, 5% CO2. 
During this time, a cell suspension of 5 × 105 cells/mL was prepared in normal cell culture media for each cell 
line. Once the Matrigel had set, the transwells were inverted and placed onto the lid of the 24-well plate. Next 
100 μL of the cell suspension (5 × 104 cells) was pipetted onto the underside of the filter. The transwells were then 
carefully covered with the base of the plate and placed (inverted) in an incubator at 37 °C, 5% CO2 for 3 hr to allow 
the cells to attach to the transwell. After the incubation period, the plate was turned the right way up and each 
transwell dipped into 1 mL 1% serum media to wash; this was repeated 3 times. The transwell was left in the final 
wash media and 100 μL normal cell culture media was added to the top of the transwell (on top of the Matrigel). 
The plate was then incubated at 37 °C, 5% CO2 for 5 days. On the 5th day SYTO™9 green fluorescent nucleic acid 
stain was diluted 1/2000 into 1% serum media in a falcon tube and vortexed. Next 0.5 mL of this solution was 
added to the wells of a 24-well plate. The plate was removed from the incubator and a transwell was added to each 
of the wells with SYTO™9 media. Then 0.5 mL of the SYTO™9/media solution was pipetted onto the top of each 
transwell to submerge the gel in staining solution. The plate was then incubated for at least 1 hour at 37oC with 5% 
CO2 and imaged immediately afterwards.
Imaging and quantification of inverse invasion assays. Transwells were placed on a thin coverslip 
and images were acquired on a Nikon Confocal A1R confocal microscope using a 20X NA 0.75 objective. The 
microscope is equipped with a 405 nm diode, Argon laser and 561 and 648 nm laser lines and four photomul-
tiplier tubes. Data were acquired using NIS Elements AR software (Nikon Instruments Europe, Netherlands). 
Images were scanned at 1x zoom, 0.25 speed and 1x line average. Optical sections were scanned at 15 μm intervals 
(Z-steps) moving up from the underside of the filter into the Matrigel. The percentage area covered by cells in 
each Z-step image was quantified in Image J using the thresholding feature. For quantification purposes, only 
cells in the Z-step 45μm or above were considered invasive as described previously13. Three separate assays were 
carried out per cell line giving 3 biological repeats with four Z-series taken for each sample per assay.
Collagen/fibroblast organotypic invasion assay. Collagen I was prepared from rat tails as described by 
Timpson et al.41. A confluent T75 flask of fibroblasts was passaged and a cell suspension of 1 × 106 cells prepared. 
The fibroblasts were then centrifuged at 400xg for 5 min. During this time, the collagen mix was prepared and all 
components kept on ice to ensure the collagen did not set; 3 mL MEM (10 × ) was added to 25 mL rat tail collagen 
I (approximately 2.6 mg/mL). Then 0.25 M NaOH (in-house) was added dropwise whilst gently mixing until the 
collagen mix turned orange but not pink (approximately 2.5 mL NaOH). The fibroblasts were resuspended in 
3 mL FCS, added to the collagen solution and gently mixed. 2.5 mL of the collagen/fibroblast mixture was then 
quickly added to each well of two 6-well plates avoiding any bubbles. The plates were incubated at 37 °C, 5% CO2 
for 10 min to allow the mixture to set. The collagen/fibroblast matrix was then detached from the sides of the wells 
and 1 mL of fibroblast culture media carefully added on top of the matrix. The plates were incubated at 37 °C, 5% 
CO2 for approximately 8 days to allow the collagen/fibroblast matrix to contract to 1.5 cm diameter.
Once the collagen/fibroblast matrices had contracted, blunt forceps were used to gently move them to a 
24-well plate. All cell lines were then split and resuspended in normal growth media at approximately 8 × 104/mL. 
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1 mL of the cell suspension was then seeded on top of the matrix. The 24-well plate was then incubated at 37 °C 
with 5% CO2 for 5 days to allow cells to grow confluent.
Tripods were made out of stainless steel grids and autoclaved prior to use. The sterile grids were placed into 
a 6 cm dish and normal cell culture media added to a level just above the grid. Using blunt forceps the collagen/
fibroblast matrix was transferred to the grid and the media gently aspirated so that the bottom of the matrix is 
in contact with media but not submerged. This creates an air/liquid interface to facilitate invasion. Dishes were 
incubated at 37 °C with 5% CO2 for 10 days to allow the cells to invade. After 10 days the matrix was removed 
from the grid and cut in half using a scalpel. The collagen matrix was then added to a falcon tube with 5 mL 4% 
(w/v) paraformaldehyde to fix overnight.
Histopathology. The fixed collagen/fibroblast matrix was embedded in wax, sectioned and stained with hae-
matoxylin and eosin (H&E) by the CRUK Edinburgh Centre Pathology & Phenomics Lab. Stained sections were 
imaged on the Nanozoomer XR model, data captured using NDP scan v 3.1. 40x magnification.
statistical analysis. All statistical analysis was carried out in SPSS and graphs created in GraphPad Prism 
unless otherwise stated. The Kolmogorov-Smirnov (KS) test was used to determine the normality of the data. For 
normally distributed data (KS: p > 0.05), parametric tests such as the independent samples t-test were used. For 
non-normally distributed data (KS: p < 0.05), the non-parametric Mann-Whitney U test was used. Significance 
was set at p < 0.05 for all statistical analyses. Wound healing data were analysed using two-way repeated measures 
ANOVA (GraphPad Prism); the normality of the data was assumed and limitations of this are acknowledged.
Data Availability
All data generated or analysed during this study are included in this published article.
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